new england journal of medicine tirzepatide In the SURMOUNT-1 trial (published in NEJM in July 2022), adults with #obesity treated with weekly tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor Read now: The SURPASS-EARLY trial
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15






















